Sequana Medical NV
Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid over… Read more
Sequana Medical NV (SEQUA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.254x
Based on the latest financial reports, Sequana Medical NV (SEQUA) has a cash flow conversion efficiency ratio of 0.254x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-9.93 Million) by net assets (€-39.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sequana Medical NV - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Sequana Medical NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sequana Medical NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sequana Medical NV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
3P Learning Ltd
AU:3PL
|
0.087x |
|
PASSUS S.A. ZY-1
F:71X
|
N/A |
|
Bookook Steel
KO:026940
|
-0.019x |
|
Jindalee Lithium Ltd
AU:JLL
|
-0.060x |
|
ALFORMER Industrial Co. Ltd.
TWO:4558
|
0.054x |
|
PT Pelayaran Tamarin Samudra Tbk
JK:TAMU
|
0.018x |
|
Catena Media plc
OTCGREY:CTTMF
|
0.013x |
|
QUEST RESOUR.HLDG DL-001
F:5ZK
|
N/A |
Annual Cash Flow Conversion Efficiency for Sequana Medical NV (2015–2024)
The table below shows the annual cash flow conversion efficiency of Sequana Medical NV from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-44.38 Million | €-20.26 Million | 0.456x | -69.43% |
| 2023-12-31 | €-19.47 Million | €-29.06 Million | 1.493x | -88.30% |
| 2022-12-31 | €-2.15 Million | €-27.48 Million | 12.763x | -57.47% |
| 2021-12-31 | €-786.92K | €-23.62 Million | 30.012x | +119.90% |
| 2020-12-31 | €112.76K | €-17.01 Million | -150.806x | -655.51% |
| 2019-12-31 | €925.93K | €-18.48 Million | -19.961x | -3891.86% |
| 2018-12-31 | €-18.76 Million | €-9.88 Million | 0.526x | -72.08% |
| 2017-12-31 | €-4.61 Million | €-8.69 Million | 1.885x | -1.40% |
| 2016-12-31 | €-6.67 Million | €-12.75 Million | 1.912x | -95.17% |
| 2015-12-31 | €-284.66K | €-11.26 Million | 39.554x | -- |